Menu
Search
|

Menu

Close
X

Minerva Neurosciences Inc NERV.OQ (NASDAQ Stock Exchange Global Market)

8.00 USD
-0.20 (-2.44%)
As of 12:00 AM EDT
chart
Previous Close 8.20
Open 8.20
Volume 25,219
3m Avg Volume 37,274
Today’s High 8.35
Today’s Low 7.95
52 Week High 9.25
52 Week Low 4.90
Shares Outstanding (mil) 38.75
Market Capitalization (mil) 313.87
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.33 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.320
FY17
-1.081
FY16
-0.985
FY15
-1.163
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.05
Price to Sales (TTM)
vs sector
--
8.10
Price to Book (MRQ)
vs sector
2.62
4.20
Price to Cash Flow (TTM)
vs sector
--
22.23
Total Debt to Equity (MRQ)
vs sector
2.22
17.32
LT Debt to Equity (MRQ)
vs sector
0.00
13.18
Return on Investment (TTM)
vs sector
-29.56
13.17
Return on Equity (TTM)
vs sector
-37.52
15.10

EXECUTIVE LEADERSHIP

Remy Luthringer
Executive Chairman of the Board, Chief Executive Officer, Since 2018
Salary: $213,761.00
Bonus: $50,000.00
Richard Russell
President, Since 2017
Salary: --
Bonus: --
Geoffrey Race
Executive Vice President and Chief Financial Officer, Since 2014
Salary: $210,000.00
Bonus: $175,000.00
Joseph Reilly
Chief Operating Officer, Vice President, Since 2014
Salary: --
Bonus: --
Frederick Ahlholm
Chief Accounting Officer, Vice President, Since 2014
Salary: $154,583.00
Bonus: $75,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1601 Trapelo Rd Ste 286
WALTHAM   MA   02451-7337

Phone: +1617.6007373

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.

SPONSORED STORIES